Detailed comparison of phenotype between male patients carrying variants in exons 1-14 and ORF15 of RPGR

Objective: To compare in detail the severity of illness among patients carrying the variant in exon 1-14 and ORF15 of retinitis pigmentosa GTPase regulator (RPGR).


Methods: Systematic generation sequencing analysis of the data, Sanger sequencing validation and segregation analysis used to identify variants of a pathogen. detailed eye examination, including Electroretinograms, fundus photography, fundus autofluorescence and optical coherence tomography performed. statistical analysis, including adjustment for age and comparison, is based on the level of cross-sectional study to compare the severity of disease between the two groups RPGR variants variants.
Results: Sixty-two variants identified in RPGR in 86 patients from 77 unrelated families. Twenty-nine (37.7%) have the variant in RPGR-exons 1-14 (group 1) and 48 (62.3%) in RPGR-ORF15 (group 2).

Eighty-four patients were diagnosed with X-linked retinitis pigmentosa and only two patients with cone-rod dystrophy. LogMAR visual acuity increased by 0,035 and 0,022 each year on average in group 1 and group 2, respectively. Group 2 patients had visual acuity better with logMAR average difference 0.4378, significant after adjustment for age (P <0.01). Good value log (wide zone ellipsoid) or central retinal thickness was significantly correlated with a variant of the grouping after considering the effect of the variable age (P = 0.56 and 0.40, respectively). ball refractive errors did not differ significantly between the two groups of variants (P = 0.17).

Autofluorescence patterns including ring hyperfluorescent in the posterior pole, spread hyperfluorescence in the macular region, and autofluorescence macular fovea dark with or without hyperfluorescence. Age and the proportion of fundus autofluorescence patterns between the two groups of variants were significantly different (P <0.01).


Conclusion: Patients with a variant in exon 1-14 maintained visual acuity less than patients with ORF15 variants and deteriorate faster. However, the width of the zone ellipsoid, central retinal thickness and refraction were comparable between the two groups. Autofluorescence patterns and variants associated with age grouping.

 Detailed comparison of phenotype between male patients carrying variants in exons 1-14 and ORF15 of RPGR
Detailed comparison of phenotype between male patients carrying variants in exons 1-14 and ORF15 of RPGR

Genotypic and phenotypic characteristics in Chinese patients with Bardet-Biedl syndrome

Objective: To investigate the complex and different phenotypes in seven Chinese patients diagnosed with Bardet-Biedl syndrome (BBS) and carrying pathogenic mutations.


Methods: Seventy-related BBS patients enrolled. medical history and their eyes examined, and a comprehensive clinical examination, such as fundus photography, optical coherence tomography, and medical imaging, performed. A panel specific enrichment hereditary eye disease based on exome-capture technology used to gather and strengthen the protein-coding regions of the genes targeted 441 hereditary eye disease, followed by high-throughput sequencing using Illumina HiSeq platform.


Results: All patients exhibited a major clinical phenotype BBS. BBS seven mutations found in five patients (BBS7 in two patients, BBS10 in two patients, BBS12 in one patient), for level detection of 71% (5/7). New rate for mutations known BBS is 5: 2.

ABO Antibody (Blood Group Antigen B)

V2551SAF-100UG 100 ug
EUR 499
Description: The antibody HEB-29 reacts with human blood group B. The specificity of the antibody HEB-29 was confirmed by comparison of specificity and reactivity to standard reagent using >5.000 samples of blood. mAb HEB-29 shows specific staining of erythrocytes and vascular epithelium of blood group B controls and no staining in group A controls. It is applicable for tissue staining in tumor patients with blood groups B and AB. Blood group antigens are generally defined as molecules formed by sequential addition of saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and certain epithelial cells. The A, B and H antigens are reported to undergo modulation during malignant cellular transformation. Blood group related antigens represent a group of carbohydrate determinants carried on both glycolipids and glycoproteins. They are usually mucin type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Sixteen genetically and biosynthetically distinct but inter related specificities belong to this group of antigens, including A, B, H, Lewis A, Lewis B, Lewis X, Lewis Y, and precursor type 1 chain antigens.

ABO Antibody (Blood Group Antigen B)

V2552-100UG 100 ug
EUR 499
Description: The antibody HEB-20 reacts with human blood group B. The specificity of the antibody HEB-20 was confirmed by comparison of specificity and reactivity to standard reagent using >5.000 samples of blood. The mAb HEB-20 shows specific staining of erythrocytes and vascular epithelium of blood group B controls and no staining in group A controls. This mAb is applicable for tissue staining in tumor patients with blood groups B and AB. Blood group antigens are generally defined as molecules formed by sequential addition of saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and certain epithelial cells. The A, B and H antigens are reported to undergo modulation during malignant cellular transformation. Blood group related antigens represent a group of carbohydrate determinants carried on both glycolipids and glycoproteins. They are usually mucin type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Sixteen genetically and biosynthetically distinct but inter related specificities belong to this group of antigens, including A, B, H, Lewis A, Lewis B, Lewis X, Lewis Y, and precursor type 1 chain antigens.

ABO Antibody (Blood Group Antigen B)

V2552-20UG 20 ug
EUR 219
Description: The antibody HEB-20 reacts with human blood group B. The specificity of the antibody HEB-20 was confirmed by comparison of specificity and reactivity to standard reagent using >5.000 samples of blood. The mAb HEB-20 shows specific staining of erythrocytes and vascular epithelium of blood group B controls and no staining in group A controls. This mAb is applicable for tissue staining in tumor patients with blood groups B and AB. Blood group antigens are generally defined as molecules formed by sequential addition of saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and certain epithelial cells. The A, B and H antigens are reported to undergo modulation during malignant cellular transformation. Blood group related antigens represent a group of carbohydrate determinants carried on both glycolipids and glycoproteins. They are usually mucin type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Sixteen genetically and biosynthetically distinct but inter related specificities belong to this group of antigens, including A, B, H, Lewis A, Lewis B, Lewis X, Lewis Y, and precursor type 1 chain antigens.

ABO Antibody (Blood Group Antigen B)

V2552IHC-7ML 7 ml
EUR 499
Description: The antibody HEB-20 reacts with human blood group B. The specificity of the antibody HEB-20 was confirmed by comparison of specificity and reactivity to standard reagent using >5.000 samples of blood. The mAb HEB-20 shows specific staining of erythrocytes and vascular epithelium of blood group B controls and no staining in group A controls. This mAb is applicable for tissue staining in tumor patients with blood groups B and AB. Blood group antigens are generally defined as molecules formed by sequential addition of saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and certain epithelial cells. The A, B and H antigens are reported to undergo modulation during malignant cellular transformation. Blood group related antigens represent a group of carbohydrate determinants carried on both glycolipids and glycoproteins. They are usually mucin type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Sixteen genetically and biosynthetically distinct but inter related specificities belong to this group of antigens, including A, B, H, Lewis A, Lewis B, Lewis X, Lewis Y, and precursor type 1 chain antigens.

ABO Antibody (Blood Group Antigen B)

V2552SAF-100UG 100 ug
EUR 499
Description: The antibody HEB-20 reacts with human blood group B. The specificity of the antibody HEB-20 was confirmed by comparison of specificity and reactivity to standard reagent using >5.000 samples of blood. The mAb HEB-20 shows specific staining of erythrocytes and vascular epithelium of blood group B controls and no staining in group A controls. This mAb is applicable for tissue staining in tumor patients with blood groups B and AB. Blood group antigens are generally defined as molecules formed by sequential addition of saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and certain epithelial cells. The A, B and H antigens are reported to undergo modulation during malignant cellular transformation. Blood group related antigens represent a group of carbohydrate determinants carried on both glycolipids and glycoproteins. They are usually mucin type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Sixteen genetically and biosynthetically distinct but inter related specificities belong to this group of antigens, including A, B, H, Lewis A, Lewis B, Lewis X, Lewis Y, and precursor type 1 chain antigens.

anti-B human blood group antigen IgM

140-A-01mg 0,1 mg
EUR 321
Description: anti-B human blood group antigen IgM

anti-B human blood group antigen IgM

140-A-1000ug 1000 ug
EUR 1539
Description: anti-B human blood group antigen IgM

Blood group antigen B(HEB-29) Antibody

BNC041065-100 100uL
EUR 238.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF405S conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC041065-500 500uL
EUR 652.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF405S conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNCAP1065-100 100uL
EUR 238.8
Description: Primary antibody against Blood group antigen B(HEB-29), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNCAP1065-500 500uL
EUR 652.8
Description: Primary antibody against Blood group antigen B(HEB-29), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNCB1065-100 100uL
EUR 238.8
Description: Primary antibody against Blood group antigen B(HEB-29), Biotin conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNCB1065-500 500uL
EUR 652.8
Description: Primary antibody against Blood group antigen B(HEB-29), Biotin conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNCP1065-250 250uL
EUR 459.6
Description: Primary antibody against Blood group antigen B(HEB-29), PerCP conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNCR1065-250 250uL
EUR 459.6
Description: Primary antibody against Blood group antigen B(HEB-29), RPE conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC941065-100 100uL
EUR 238.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF594 conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC941065-500 500uL
EUR 652.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF594 conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNCA1065-250 250uL
EUR 459.6
Description: Primary antibody against Blood group antigen B(HEB-29), APC conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC811065-100 100uL
EUR 238.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF680R conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC811065-500 500uL
EUR 652.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF680R conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNUB1065-100 100uL
EUR 250.8
Description: Primary antibody against Blood group antigen B(HEB-29), Concentration: 0.2mg/mL

Blood group antigen B(HEB-29) Antibody

BNUB1065-500 500uL
EUR 549.6
Description: Primary antibody against Blood group antigen B(HEB-29), Concentration: 0.2mg/mL

Blood group antigen B(HEB-29) Antibody

BNCH1065-100 100uL
EUR 238.8
Description: Primary antibody against Blood group antigen B(HEB-29), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNCH1065-500 500uL
EUR 652.8
Description: Primary antibody against Blood group antigen B(HEB-29), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC881065-100 100uL
EUR 238.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF488A conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC881065-500 500uL
EUR 652.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF488A conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC611065-100 100uL
EUR 238.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF660R conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC611065-500 500uL
EUR 652.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF660R conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC681065-100 100uL
EUR 238.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF568 conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC681065-500 500uL
EUR 652.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF568 conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC471065-100 100uL
EUR 238.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF647 conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC471065-500 500uL
EUR 652.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF647 conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC401065-100 100uL
EUR 238.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF640R conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC401065-500 500uL
EUR 652.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF640R conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC431065-100 100uL
EUR 238.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF543 conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC431065-500 500uL
EUR 652.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF543 conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC551065-100 100uL
EUR 238.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF555 conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC551065-500 500uL
EUR 652.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF555 conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC801065-100 100uL
EUR 238.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF680 conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC801065-500 500uL
EUR 652.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF680 conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC051065-100 100uL
EUR 238.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF405M conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC051065-500 500uL
EUR 652.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF405M conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC701065-100 100uL
EUR 238.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF770 conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNC701065-500 500uL
EUR 652.8
Description: Primary antibody against Blood group antigen B(HEB-29), CF770 conjugate, Concentration: 0.1mg/mL

Blood group antigen B(HEB-29) Antibody

BNUM1065-50 50uL
EUR 474
Description: Primary antibody against Blood group antigen B(HEB-29), 1mg/mL

Anti-Human blood group antigen B antibody

STJ16100162 1 mL
EUR 382.8

Blood Group B Antibody

abx140274-10ml 1.0 ml
EUR 360

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC040296-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF405S conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC040296-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF405S conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC050296-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF405M conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC050296-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF405M conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNCAP0296-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNCAP0296-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNCB0296-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), Biotin conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNCB0296-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), Biotin conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNCP0296-250 250uL
EUR 459.6
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), PerCP conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNCR0296-250 250uL
EUR 459.6
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), RPE conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC940296-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF594 conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC940296-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF594 conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNCA0296-250 250uL
EUR 459.6
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), APC conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC810296-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF680R conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC810296-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF680R conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNUB0296-100 100uL
EUR 250.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), Concentration: 0.2mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNUB0296-500 500uL
EUR 549.6
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), Concentration: 0.2mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNCH0296-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNCH0296-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC880296-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF488A conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC880296-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF488A conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC680296-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF568 conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC680296-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF568 conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC470296-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF647 conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC470296-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF647 conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC430296-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF543 conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC430296-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF543 conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC610296-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF660R conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC610296-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF660R conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC800296-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF680 conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC800296-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF680 conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC400296-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF640R conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC400296-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF640R conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC550296-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF555 conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC550296-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF555 conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC700296-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF770 conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNC700296-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), CF770 conjugate, Concentration: 0.1mg/mL

Blood Group Antigen B (CD173) (HEB-20) Antibody

BNUM0296-50 50uL
EUR 474
Description: Primary antibody against Blood Group Antigen B (CD173)(HEB-20), 1mg/mL

anti-Blood Group Kell Antigen

YF-PA12828 50 ul
EUR 435.6
Description: Mouse polyclonal to Blood Group Kell Antigen

Monoclonal Blood Group Antigen Lewis B Antibody, Clone: SPM194

AMM00726G 7 ml
EUR 580.8
Description: A Monoclonal antibody against Human Blood Group Antigen Lewis B. The antibodies are raised in Mouse and are from clone SPM194. This antibody is applicable in IHC, IF

Blood Group Lewis b Antibody

abx140259-01mg 0.1 mg
EUR 393.6

Anti-Blood Group B antibody

STJ16100984 100 µg
EUR 424.8

anti-Blood Group Lewis b

YF-PA11878 50 ug
EUR 435.6
Description: Mouse polyclonal to Blood Group Lewis b

anti-Blood Group Lewis b

YF-PA11879 100 ug
EUR 483.6
Description: Rabbit polyclonal to Blood Group Lewis b

Blood Group H ab Antigen antibody

10R-H103a 100 ug
EUR 327.6
Description: Mouse monoclonal Blood Group H ab Antigen antibody

Anti-Blood Group Kell Antigen (4B10)

YF-MA13914 100 ug
EUR 435.6
Description: Mouse monoclonal to Blood Group Kell Antigen

ABO Antibody (Blood Group Antigen A)

V2549-100UG 100 ug
EUR 499
Description: This antibody recognizes human blood group A (monofucosyl and difucosyl A antigens with chain types 1, 2, 3, 4, 5, 6) and Forssmann antigen. It is also reactive with the immuno-dominant A trisaccharide. Blood group antigen expression in human colon cancer was studied by means of two monoclonal antibodies of broad anti-A (HE-14) and anti-type 3 and type 4 chain-based A and H (HE-10) specificity. These antigens were proved to re-appear in tumors of the distal colon, the HE-10 antibody reacting more frequently (9 out of 12 samples) than HE-14 (5 out of 12 samples) and frequently with supra-nuclear staining of the cytoplasm probably in those places of the Golgi apparatus where carbohydrate antigens are synthesized. This staining pattern is characteristic of HE-10 in normal colonic mucosa as well. With HE-14, staining was often absent in less differentiated tumors, while HE-10 did react in such tumors. In some cases, these two antibodies gave different staining patterns in parallel sections from the same tissue sample, primarily at the cellular level. Three out of 12 cases showed blood group antigen expression in the mucosa of the distal colon adjacent to the tumor only when HE-10 mAb was used.

ABO Antibody (Blood Group Antigen A)

V2549-20UG 20 ug
EUR 219
Description: This antibody recognizes human blood group A (monofucosyl and difucosyl A antigens with chain types 1, 2, 3, 4, 5, 6) and Forssmann antigen. It is also reactive with the immuno-dominant A trisaccharide. Blood group antigen expression in human colon cancer was studied by means of two monoclonal antibodies of broad anti-A (HE-14) and anti-type 3 and type 4 chain-based A and H (HE-10) specificity. These antigens were proved to re-appear in tumors of the distal colon, the HE-10 antibody reacting more frequently (9 out of 12 samples) than HE-14 (5 out of 12 samples) and frequently with supra-nuclear staining of the cytoplasm probably in those places of the Golgi apparatus where carbohydrate antigens are synthesized. This staining pattern is characteristic of HE-10 in normal colonic mucosa as well. With HE-14, staining was often absent in less differentiated tumors, while HE-10 did react in such tumors. In some cases, these two antibodies gave different staining patterns in parallel sections from the same tissue sample, primarily at the cellular level. Three out of 12 cases showed blood group antigen expression in the mucosa of the distal colon adjacent to the tumor only when HE-10 mAb was used.

ABO Antibody (Blood Group Antigen A)

V2549SAF-100UG 100 ug
EUR 499
Description: This antibody recognizes human blood group A (monofucosyl and difucosyl A antigens with chain types 1, 2, 3, 4, 5, 6) and Forssmann antigen. It is also reactive with the immuno-dominant A trisaccharide. Blood group antigen expression in human colon cancer was studied by means of two monoclonal antibodies of broad anti-A (HE-14) and anti-type 3 and type 4 chain-based A and H (HE-10) specificity. These antigens were proved to re-appear in tumors of the distal colon, the HE-10 antibody reacting more frequently (9 out of 12 samples) than HE-14 (5 out of 12 samples) and frequently with supra-nuclear staining of the cytoplasm probably in those places of the Golgi apparatus where carbohydrate antigens are synthesized. This staining pattern is characteristic of HE-10 in normal colonic mucosa as well. With HE-14, staining was often absent in less differentiated tumors, while HE-10 did react in such tumors. In some cases, these two antibodies gave different staining patterns in parallel sections from the same tissue sample, primarily at the cellular level. Three out of 12 cases showed blood group antigen expression in the mucosa of the distal colon adjacent to the tumor only when HE-10 mAb was used.

ABO Antibody (Blood Group Antigen A)

V2550-100UG 100 ug
EUR 499
Description: This antibody recognizes human blood group A (monofucosyl and difucosyl A antigens with chain types 1, 2, 3, 4, 5, 6) and Forssmann antigen. Blood-group antigens are generally defined as molecules formed by sequential addition of saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and certain epithelial cells. The A, B and H antigens are reported to undergo modulation during malignant cellular transformation. Blood group related antigens represent a group of carbohydrate determinants carried on both glycolipids and glycoproteins. They are usually mucin-type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Sixteen genetically and biosynthetically distinct but inter-related specificities belong to this group of antigens, including A, B, H, Lewis A, Lewis B, Lewis X, Lewis Y, and precursor type 1 chain antigens.

ABO Antibody (Blood Group Antigen A)

V2550-20UG 20 ug
EUR 219
Description: This antibody recognizes human blood group A (monofucosyl and difucosyl A antigens with chain types 1, 2, 3, 4, 5, 6) and Forssmann antigen. Blood-group antigens are generally defined as molecules formed by sequential addition of saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and certain epithelial cells. The A, B and H antigens are reported to undergo modulation during malignant cellular transformation. Blood group related antigens represent a group of carbohydrate determinants carried on both glycolipids and glycoproteins. They are usually mucin-type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Sixteen genetically and biosynthetically distinct but inter-related specificities belong to this group of antigens, including A, B, H, Lewis A, Lewis B, Lewis X, Lewis Y, and precursor type 1 chain antigens.

ABO Antibody (Blood Group Antigen A)

V2550SAF-100UG 100 ug
EUR 499
Description: This antibody recognizes human blood group A (monofucosyl and difucosyl A antigens with chain types 1, 2, 3, 4, 5, 6) and Forssmann antigen. Blood-group antigens are generally defined as molecules formed by sequential addition of saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and certain epithelial cells. The A, B and H antigens are reported to undergo modulation during malignant cellular transformation. Blood group related antigens represent a group of carbohydrate determinants carried on both glycolipids and glycoproteins. They are usually mucin-type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Sixteen genetically and biosynthetically distinct but inter-related specificities belong to this group of antigens, including A, B, H, Lewis A, Lewis B, Lewis X, Lewis Y, and precursor type 1 chain antigens.

ABO Antibody (Blood Group Antigen A)

V2553-100UG 100 ug
EUR 499
Description: This mAb preferably reacts with determinants of chain A and H type 3 (Gal1-3GalNAc-R) and 4 (Gal1-3GalNAc-R), but not with type 1 and 2 chain structures. It is not reactive with immuno-dominant A trisaccharide. This mAb is applicable for tissue staining in tumor patients with blood groups A and AB. It shows a highly heterogeneous reactivity in human colon tumor tissue and adjacent mucosa. Blood-group antigens are generally defined as molecules formed by sequential addition of saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and certain epithelial cells. The A, B and H antigens are reported to undergo modulation during malignant cellular transformation. Blood group related antigens represent a group of carbohydrate determinants carried on both glycolipids and glycoproteins. They are usually mucin-type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Sixteen genetically and biosynthetically distinct but inter-related specificities belong to this group of antigens, including A, B, H, Lewis A, Lewis B, Lewis X, Lewis Y, and precursor type 1 chain antigens.

ABO Antibody (Blood Group Antigen A)

V2553-20UG 20 ug
EUR 219
Description: This mAb preferably reacts with determinants of chain A and H type 3 (Gal1-3GalNAc-R) and 4 (Gal1-3GalNAc-R), but not with type 1 and 2 chain structures. It is not reactive with immuno-dominant A trisaccharide. This mAb is applicable for tissue staining in tumor patients with blood groups A and AB. It shows a highly heterogeneous reactivity in human colon tumor tissue and adjacent mucosa. Blood-group antigens are generally defined as molecules formed by sequential addition of saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and certain epithelial cells. The A, B and H antigens are reported to undergo modulation during malignant cellular transformation. Blood group related antigens represent a group of carbohydrate determinants carried on both glycolipids and glycoproteins. They are usually mucin-type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Sixteen genetically and biosynthetically distinct but inter-related specificities belong to this group of antigens, including A, B, H, Lewis A, Lewis B, Lewis X, Lewis Y, and precursor type 1 chain antigens.

ABO Antibody (Blood Group Antigen A)

V2553SAF-100UG 100 ug
EUR 499
Description: This mAb preferably reacts with determinants of chain A and H type 3 (Gal1-3GalNAc-R) and 4 (Gal1-3GalNAc-R), but not with type 1 and 2 chain structures. It is not reactive with immuno-dominant A trisaccharide. This mAb is applicable for tissue staining in tumor patients with blood groups A and AB. It shows a highly heterogeneous reactivity in human colon tumor tissue and adjacent mucosa. Blood-group antigens are generally defined as molecules formed by sequential addition of saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and certain epithelial cells. The A, B and H antigens are reported to undergo modulation during malignant cellular transformation. Blood group related antigens represent a group of carbohydrate determinants carried on both glycolipids and glycoproteins. They are usually mucin-type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Sixteen genetically and biosynthetically distinct but inter-related specificities belong to this group of antigens, including A, B, H, Lewis A, Lewis B, Lewis X, Lewis Y, and precursor type 1 chain antigens.

ABO Antibody (Blood Group Antigen A)

V2554-100UG 100 ug
EUR 499
Description: This mAb preferably reacts with determinants of chain A and H type 3 (Gal1-3GalNAc-R) and 4 (Gal1-3GalNAc-R), but not with type 1 and 2 chain structures. It is not reactive with immuno-dominant A trisaccharide. This mAb is applicable for tissue staining in tumor patients with blood groups A and AB. It shows a highly heterogeneous reactivity in human colon tumor tissue and adjacent mucosa. Blood-group antigens are generally defined as molecules formed by sequential addition of saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and certain epithelial cells. The A, B and H antigens are reported to undergo modulation during malignant cellular transformation. Blood group related antigens represent a group of carbohydrate determinants carried on both glycolipids and glycoproteins. They are usually mucin-type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Sixteen genetically and biosynthetically distinct but inter-related specificities belong to this group of antigens, including A, B, H, Lewis A, Lewis B, Lewis X, Lewis Y, and precursor type 1 chain antigens.

ABO Antibody (Blood Group Antigen A)

V2554-20UG 20 ug
EUR 219
Description: This mAb preferably reacts with determinants of chain A and H type 3 (Gal1-3GalNAc-R) and 4 (Gal1-3GalNAc-R), but not with type 1 and 2 chain structures. It is not reactive with immuno-dominant A trisaccharide. This mAb is applicable for tissue staining in tumor patients with blood groups A and AB. It shows a highly heterogeneous reactivity in human colon tumor tissue and adjacent mucosa. Blood-group antigens are generally defined as molecules formed by sequential addition of saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and certain epithelial cells. The A, B and H antigens are reported to undergo modulation during malignant cellular transformation. Blood group related antigens represent a group of carbohydrate determinants carried on both glycolipids and glycoproteins. They are usually mucin-type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Sixteen genetically and biosynthetically distinct but inter-related specificities belong to this group of antigens, including A, B, H, Lewis A, Lewis B, Lewis X, Lewis Y, and precursor type 1 chain antigens.

ABO Antibody (Blood Group Antigen A)

V2554IHC-7ML 7 ml
EUR 499
Description: This mAb preferably reacts with determinants of chain A and H type 3 (Gal1-3GalNAc-R) and 4 (Gal1-3GalNAc-R), but not with type 1 and 2 chain structures. It is not reactive with immuno-dominant A trisaccharide. This mAb is applicable for tissue staining in tumor patients with blood groups A and AB. It shows a highly heterogeneous reactivity in human colon tumor tissue and adjacent mucosa. Blood-group antigens are generally defined as molecules formed by sequential addition of saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and certain epithelial cells. The A, B and H antigens are reported to undergo modulation during malignant cellular transformation. Blood group related antigens represent a group of carbohydrate determinants carried on both glycolipids and glycoproteins. They are usually mucin-type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Sixteen genetically and biosynthetically distinct but inter-related specificities belong to this group of antigens, including A, B, H, Lewis A, Lewis B, Lewis X, Lewis Y, and precursor type 1 chain antigens.

ABO Antibody (Blood Group Antigen A)

V2554SAF-100UG 100 ug
EUR 499
Description: This mAb preferably reacts with determinants of chain A and H type 3 (Gal1-3GalNAc-R) and 4 (Gal1-3GalNAc-R), but not with type 1 and 2 chain structures. It is not reactive with immuno-dominant A trisaccharide. This mAb is applicable for tissue staining in tumor patients with blood groups A and AB. It shows a highly heterogeneous reactivity in human colon tumor tissue and adjacent mucosa. Blood-group antigens are generally defined as molecules formed by sequential addition of saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and certain epithelial cells. The A, B and H antigens are reported to undergo modulation during malignant cellular transformation. Blood group related antigens represent a group of carbohydrate determinants carried on both glycolipids and glycoproteins. They are usually mucin-type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Sixteen genetically and biosynthetically distinct but inter-related specificities belong to this group of antigens, including A, B, H, Lewis A, Lewis B, Lewis X, Lewis Y, and precursor type 1 chain antigens.

Monoclonal Blood Group Antigen B (CD173) Antibody, Clone: HEB-20

AMM00790G 7 ml
EUR 580.8
Description: A Monoclonal antibody against Human Blood Group Antigen B (CD173). The antibodies are raised in Mouse and are from clone HEB-20. This antibody is applicable in IHC, IF

Anti-Blood Group Lewis b Purified

11-386-C025 0.025 mg
EUR 108

Anti-Blood Group Lewis b Purified

11-386-C100 0.1 mg
EUR 168

Anti-Blood Group B Culture supernatant

99-806-L001 1.0 ml
EUR 146.4

Blood Group Lewis b Antibody / FUT3

V2520-100UG 100 ug
EUR 499
Description: The Lewis histo-blood group system comprises a set of fucosylated glycosphingolipids that are synthesized by exocrine epithelial cells and circulate in body fluids. The glycosphingolipids function in embryogenesis, tissue differentiation, tumor metastasis, inflammation, and bacterial adhesion. They are secondarily absorbed to red blood cells giving rise to their Lewis phenotype. This gene is a member of the fucosyltransferase family, which catalyzes the addition of fucose to precursor polysaccharides in the last step of Lewis antigen biosynthesis. It encodes an enzyme with alpha(1,3)-fucosyltransferase and alpha(1,4)-fucosyltransferase activities. Lewis blood group antigens are carbohydrate moieties structurally integrated in mucous secretions. Lewis antigen system alterations have been described in gastric carcinoma and associated lesions. Anomalous expression of Lewis B antigen has been found in some non-secretory gastric carcinomas and colorectal cancers.

Blood Group Lewis b Antibody / FUT3

V2520-20UG 20 ug
EUR 219
Description: The Lewis histo-blood group system comprises a set of fucosylated glycosphingolipids that are synthesized by exocrine epithelial cells and circulate in body fluids. The glycosphingolipids function in embryogenesis, tissue differentiation, tumor metastasis, inflammation, and bacterial adhesion. They are secondarily absorbed to red blood cells giving rise to their Lewis phenotype. This gene is a member of the fucosyltransferase family, which catalyzes the addition of fucose to precursor polysaccharides in the last step of Lewis antigen biosynthesis. It encodes an enzyme with alpha(1,3)-fucosyltransferase and alpha(1,4)-fucosyltransferase activities. Lewis blood group antigens are carbohydrate moieties structurally integrated in mucous secretions. Lewis antigen system alterations have been described in gastric carcinoma and associated lesions. Anomalous expression of Lewis B antigen has been found in some non-secretory gastric carcinomas and colorectal cancers.

Blood Group Lewis b Antibody / FUT3

V2520IHC-7ML 7 ml
EUR 499
Description: The Lewis histo-blood group system comprises a set of fucosylated glycosphingolipids that are synthesized by exocrine epithelial cells and circulate in body fluids. The glycosphingolipids function in embryogenesis, tissue differentiation, tumor metastasis, inflammation, and bacterial adhesion. They are secondarily absorbed to red blood cells giving rise to their Lewis phenotype. This gene is a member of the fucosyltransferase family, which catalyzes the addition of fucose to precursor polysaccharides in the last step of Lewis antigen biosynthesis. It encodes an enzyme with alpha(1,3)-fucosyltransferase and alpha(1,4)-fucosyltransferase activities. Lewis blood group antigens are carbohydrate moieties structurally integrated in mucous secretions. Lewis antigen system alterations have been described in gastric carcinoma and associated lesions. Anomalous expression of Lewis B antigen has been found in some non-secretory gastric carcinomas and colorectal cancers.

Blood Group Lewis b Antibody / FUT3

V2520SAF-100UG 100 ug
EUR 499
Description: The Lewis histo-blood group system comprises a set of fucosylated glycosphingolipids that are synthesized by exocrine epithelial cells and circulate in body fluids. The glycosphingolipids function in embryogenesis, tissue differentiation, tumor metastasis, inflammation, and bacterial adhesion. They are secondarily absorbed to red blood cells giving rise to their Lewis phenotype. This gene is a member of the fucosyltransferase family, which catalyzes the addition of fucose to precursor polysaccharides in the last step of Lewis antigen biosynthesis. It encodes an enzyme with alpha(1,3)-fucosyltransferase and alpha(1,4)-fucosyltransferase activities. Lewis blood group antigens are carbohydrate moieties structurally integrated in mucous secretions. Lewis antigen system alterations have been described in gastric carcinoma and associated lesions. Anomalous expression of Lewis B antigen has been found in some non-secretory gastric carcinomas and colorectal cancers.

Blood Group Lewis b Antibody / FUT3

V3146-100UG 100 ug
EUR 499
Description: The Lewis histo-blood group system comprises a set of fucosylated glycosphingolipids that are synthesized by exocrine epithelial cells and circulate in body fluids. The glycosphingolipids function in embryogenesis, tissue differentiation, tumor metastasis, inflammation, and bacterial adhesion. They are secondarily absorbed to red blood cells giving rise to their Lewis phenotype. This gene is a member of the fucosyltransferase family, which catalyzes the addition of fucose to precursor polysaccharides in the last step of Lewis antigen biosynthesis. It encodes an enzyme with alpha(1,3)-fucosyltransferase and alpha(1,4)-fucosyltransferase activities. Lewis blood group antigens are carbohydrate moieties structurally integrated in mucous secretions. Lewis antigen system alterations have been described in gastric carcinoma and associated lesions. Anomalous expression of Lewis B antigen has been found in some non-secretory gastric carcinomas and colorectal cancers.

Blood Group Lewis b Antibody / FUT3

V3146-20UG 20 ug
EUR 219
Description: The Lewis histo-blood group system comprises a set of fucosylated glycosphingolipids that are synthesized by exocrine epithelial cells and circulate in body fluids. The glycosphingolipids function in embryogenesis, tissue differentiation, tumor metastasis, inflammation, and bacterial adhesion. They are secondarily absorbed to red blood cells giving rise to their Lewis phenotype. This gene is a member of the fucosyltransferase family, which catalyzes the addition of fucose to precursor polysaccharides in the last step of Lewis antigen biosynthesis. It encodes an enzyme with alpha(1,3)-fucosyltransferase and alpha(1,4)-fucosyltransferase activities. Lewis blood group antigens are carbohydrate moieties structurally integrated in mucous secretions. Lewis antigen system alterations have been described in gastric carcinoma and associated lesions. Anomalous expression of Lewis B antigen has been found in some non-secretory gastric carcinomas and colorectal cancers.

Blood Group Lewis b Antibody / FUT3

V3146IHC-7ML 7 ml
EUR 499
Description: The Lewis histo-blood group system comprises a set of fucosylated glycosphingolipids that are synthesized by exocrine epithelial cells and circulate in body fluids. The glycosphingolipids function in embryogenesis, tissue differentiation, tumor metastasis, inflammation, and bacterial adhesion. They are secondarily absorbed to red blood cells giving rise to their Lewis phenotype. This gene is a member of the fucosyltransferase family, which catalyzes the addition of fucose to precursor polysaccharides in the last step of Lewis antigen biosynthesis. It encodes an enzyme with alpha(1,3)-fucosyltransferase and alpha(1,4)-fucosyltransferase activities. Lewis blood group antigens are carbohydrate moieties structurally integrated in mucous secretions. Lewis antigen system alterations have been described in gastric carcinoma and associated lesions. Anomalous expression of Lewis B antigen has been found in some non-secretory gastric carcinomas and colorectal cancers.

Blood Group Lewis b Antibody / FUT3

V3146SAF-100UG 100 ug
EUR 499
Description: The Lewis histo-blood group system comprises a set of fucosylated glycosphingolipids that are synthesized by exocrine epithelial cells and circulate in body fluids. The glycosphingolipids function in embryogenesis, tissue differentiation, tumor metastasis, inflammation, and bacterial adhesion. They are secondarily absorbed to red blood cells giving rise to their Lewis phenotype. This gene is a member of the fucosyltransferase family, which catalyzes the addition of fucose to precursor polysaccharides in the last step of Lewis antigen biosynthesis. It encodes an enzyme with alpha(1,3)-fucosyltransferase and alpha(1,4)-fucosyltransferase activities. Lewis blood group antigens are carbohydrate moieties structurally integrated in mucous secretions. Lewis antigen system alterations have been described in gastric carcinoma and associated lesions. Anomalous expression of Lewis B antigen has been found in some non-secretory gastric carcinomas and colorectal cancers.

Rh Blood Group, D Antigen (RHD) Antibody

20-abx132208
  • EUR 543.60
  • EUR 159.60
  • EUR 1579.20
  • EUR 744.00
  • EUR 410.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Rh Blood Group D Antigen (RHD) Antibody

abx029359-400ul 400 ul
EUR 627.6

Rh Blood Group D Antigen (RHD) Antibody

abx029359-80l 80 µl
EUR 343.2

Rh Blood Group D Antigen (RHD) Antibody

20-abx323345
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

Rh Blood Group D Antigen (RHD) Antibody

20-abx318000
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Rh Blood Group, D Antigen (RHD) Antibody

20-abx174400
  • EUR 1111.20
  • EUR 560.40
  • 1 mg
  • 200 ug

Blood Group Antigen A (CD173) (33C13) Antibody

BNC041261-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen A (CD173)(33C13), CF405S conjugate, Concentration: 0.1mg/mL

Blood Group Antigen A (CD173) (33C13) Antibody

BNC041261-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen A (CD173)(33C13), CF405S conjugate, Concentration: 0.1mg/mL

Blood Group Antigen A (CD173) (33C13) Antibody

BNCAP1261-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen A (CD173)(33C13), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Blood Group Antigen A (CD173) (33C13) Antibody

BNCAP1261-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen A (CD173)(33C13), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Blood Group Antigen A (CD173) (33C13) Antibody

BNCP1261-250 250uL
EUR 459.6
Description: Primary antibody against Blood Group Antigen A (CD173)(33C13), PerCP conjugate, Concentration: 0.1mg/mL

Blood Group Antigen A (CD173) (33C13) Antibody

BNCR1261-250 250uL
EUR 459.6
Description: Primary antibody against Blood Group Antigen A (CD173)(33C13), RPE conjugate, Concentration: 0.1mg/mL

Blood Group Antigen A (CD173) (33C13) Antibody

BNC941261-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen A (CD173)(33C13), CF594 conjugate, Concentration: 0.1mg/mL

Blood Group Antigen A (CD173) (33C13) Antibody

BNC941261-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen A (CD173)(33C13), CF594 conjugate, Concentration: 0.1mg/mL

Blood Group Antigen A (CD173) (33C13) Antibody

BNCA1261-250 250uL
EUR 459.6
Description: Primary antibody against Blood Group Antigen A (CD173)(33C13), APC conjugate, Concentration: 0.1mg/mL

Blood Group Antigen A (CD173) (33C13) Antibody

BNC811261-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen A (CD173)(33C13), CF680R conjugate, Concentration: 0.1mg/mL

Blood Group Antigen A (CD173) (33C13) Antibody

BNC811261-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen A (CD173)(33C13), CF680R conjugate, Concentration: 0.1mg/mL

Blood Group Antigen A (CD173) (33C13) Antibody

BNUB1261-100 100uL
EUR 250.8
Description: Primary antibody against Blood Group Antigen A (CD173)(33C13), Concentration: 0.2mg/mL

Blood Group Antigen A (CD173) (33C13) Antibody

BNUB1261-500 500uL
EUR 549.6
Description: Primary antibody against Blood Group Antigen A (CD173)(33C13), Concentration: 0.2mg/mL

Blood Group Antigen A (CD173) (33C13) Antibody

BNCH1261-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen A (CD173)(33C13), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Blood Group Antigen A (CD173) (33C13) Antibody

BNCH1261-500 500uL
EUR 652.8
Description: Primary antibody against Blood Group Antigen A (CD173)(33C13), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Blood Group Antigen A (CD173) (33C13) Antibody

BNC881261-100 100uL
EUR 238.8
Description: Primary antibody against Blood Group Antigen A (CD173)(33C13), CF488A conjugate, Concentration: 0.1mg/mL


Conclusion: This study shows the spectrum of phenotypic and genotypic BBS patients from China, and the findings underscore the importance of obtaining a comprehensive clinical observations and molecular analyzes to ciliopathies.